Download PDF

1. Company Snapshot

1.a. Company Description

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn.Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia.Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments.


The company, through its subsidiary, BioNexus Gene Lab Sdn.Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers.The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Show Full description

1.b. Last Insights on BGLC

BioNexus Gene Lab Corp.'s recent performance was driven by its bold move to prioritize Ethereum as a strategic treasury asset, marking the company as the first Nasdaq-listed company to do so. This decision was followed by a strategic partnership with ML Tech, an AI-driven wealth management platform, to optimize the company's Ethereum-based growth strategies. The partnership demonstrates the company's commitment to technological and financial innovation, positioning it for potential growth in the digital asset space.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Financial Comparison: BioNexus Gene Lab (NASDAQ:BGLC) vs. NewGenIvf Group (NASDAQ:NIVF)

Dec -04

Source: defenseworld.net

Card image cap

BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™

Dec -03

Source: globenewswire.com

Card image cap

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization

Dec -02

Source: globenewswire.com

Card image cap

BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene

Dec -01

Source: globenewswire.com

Card image cap

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization

Nov -12

Source: globenewswire.com

Card image cap

BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities

Nov -10

Source: globenewswire.com

Card image cap

PACS Group (NYSE:PACS) versus BioNexus Gene Lab (NASDAQ:BGLC) Critical Contrast

Oct -31

Source: defenseworld.net

Card image cap

BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.

Oct -20

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (15.40%)

6. Segments

Chemrex

Expected Growth: 15.4%

The gene editing market is driven by increasing demand for precision medicine, growing investments in genomics research, and advancements in CRISPR technology. Chemrex's proprietary technology enables efficient genome modification, positioning BioNexus Gene Lab Corp. for significant growth in the gene editing market.

MRNA Scientific Malaysia

Expected Growth: 12.4%

Growing demand for mRNA-based therapies and vaccines, increasing investment in biotechnology research, and government initiatives to boost Malaysia's biotech industry drive growth for MRNA Scientific Malaysia.

7. Detailed Products

Genomic Sequencing

High-throughput DNA sequencing services for research and clinical applications

Gene Expression Analysis

Comprehensive analysis of gene expression profiles for biomarker discovery and disease diagnosis

CRISPR Gene Editing

Precise genome editing services for basic research, biotechnology, and therapeutic applications

Stem Cell Analysis

Characterization and analysis of stem cells for regenerative medicine and tissue engineering

Microbiome Analysis

Comprehensive analysis of microbial communities for human health, agriculture, and environmental applications

Bioinformatics Services

Custom bioinformatics solutions for data analysis, interpretation, and visualization

8. BioNexus Gene Lab Corp.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for BioNexus Gene Lab Corp. is medium due to the presence of alternative genetic testing services and products.

Bargaining Power Of Customers

The bargaining power of customers for BioNexus Gene Lab Corp. is low due to the specialized nature of genetic testing services and the lack of price sensitivity among customers.

Bargaining Power Of Suppliers

The bargaining power of suppliers for BioNexus Gene Lab Corp. is medium due to the presence of multiple suppliers of genetic testing equipment and reagents.

Threat Of New Entrants

The threat of new entrants for BioNexus Gene Lab Corp. is high due to the growing demand for genetic testing services and the relatively low barriers to entry.

Intensity Of Rivalry

The intensity of rivalry for BioNexus Gene Lab Corp. is high due to the presence of established competitors in the genetic testing market and the need to differentiate services and products.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 1.36%
Debt Cost 10.36%
Equity Weight 98.64%
Equity Cost 13.69%
WACC 13.64%
Leverage 1.38%

11. Quality Control: BioNexus Gene Lab Corp. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Prenetics Global

A-Score: 4.8/10

Value: 7.6

Growth: 3.4

Quality: 4.1

Yield: 0.0

Momentum: 10.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
BioNexus Gene Lab

A-Score: 4.1/10

Value: 8.0

Growth: 2.8

Quality: 4.8

Yield: 0.0

Momentum: 8.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Castle Biosciences

A-Score: 3.5/10

Value: 4.8

Growth: 8.2

Quality: 5.2

Yield: 0.0

Momentum: 1.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Qilian International Holding

A-Score: 3.3/10

Value: 7.5

Growth: 3.0

Quality: 3.4

Yield: 0.0

Momentum: 6.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Biodesix

A-Score: 2.7/10

Value: 7.6

Growth: 4.2

Quality: 3.8

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Selvita

A-Score: 2.3/10

Value: 3.5

Growth: 4.9

Quality: 3.7

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

4.1$

Current Price

4.11$

Potential

-0.00%

Expected Cash-Flows